121 related articles for article (PubMed ID: 1260757)
1. Enhancement of a tumor allograft in BALB/c x DBA/2 F1 mice by pyran copolymer.
Mohr SJ; Chirigos MA; Fuhrman F; Smith G
Cancer Res; 1976 Apr; 36(4):1315-9. PubMed ID: 1260757
[TBL] [Abstract][Full Text] [Related]
2. Immune response of BALB/c X DBA/2F1 mice to a tumor allograft during pyran copolymer-induced tumor enhancement.
Schultz RM; Woods WA; Mohr SJ; Chirigos MA
Cancer Res; 1976 May; 36(5):1641-6. PubMed ID: 1268825
[TBL] [Abstract][Full Text] [Related]
3. Inhibition and enhancement of Friend leukemia virus by pyran copolymer.
Schuller GB; Morahan PS; Snodgrass M
Cancer Res; 1975 Aug; 35(8):1915-20. PubMed ID: 1149015
[TBL] [Abstract][Full Text] [Related]
4. Specific potentiation of L1210 vaccine by pyran copolymer.
Mohr SJ; Chirigos MA; Smith GT; Fuhrman FS
Cancer Res; 1976 Jun; 36(6):2035-9. PubMed ID: 1268855
[TBL] [Abstract][Full Text] [Related]
5. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppression by pyran copolymer: correlation with production of cytotoxic macrophages.
Harmel RP; zbar B
J Natl Cancer Inst; 1975 Apr; 54(4):989-92. PubMed ID: 1127729
[TBL] [Abstract][Full Text] [Related]
7. Cellular and serum involvement in protection against Friend leukemia virus.
Schuller GB; Morahan PS
Cancer Res; 1977 Nov; 37(11):4064-9. PubMed ID: 908040
[TBL] [Abstract][Full Text] [Related]
8. Macrophage involvement in the protective effect of pyran copolymer against the Madison lung carcinoma (M109).
Schultz RM; Papamatheakis JD; Luetzeler J; Ruiz P; Chirigos MA
Cancer Res; 1977 Feb; 37(2):358-64. PubMed ID: 832262
[TBL] [Abstract][Full Text] [Related]
9. Effects of pyran copolymer on leukemogenesis in immunosuppressed AKR mice.
Hirsch MS; Black PH; Wood ML; Monaco AP
J Immunol; 1973 Jul; 111(1):91-5. PubMed ID: 4351539
[No Abstract] [Full Text] [Related]
10. Tumor induction by immunologically activated murine leukemia virus: cellular immunity early in the graft-vs-host reaction.
Ruddle NH; Armstrong MY; Richards FF
J Immunol; 1974 Feb; 112(2):706-15. PubMed ID: 4149884
[No Abstract] [Full Text] [Related]
11. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
12. Response of murine leukemia to combined BCNU-maleic anhydride-vinyl ether (MVE) adjuvant therapy and correlation with macrophage activation by MVE in the in vitro growth inhibition assay.
Dean JH; Padarathsingh ML; Keys L
Cancer Treat Rep; 1978 Nov; 62(11):1807-16. PubMed ID: 728898
[No Abstract] [Full Text] [Related]
13. Prolongation of chemotherapeutically induced remission of a syneneic murine leukemia by L-2,3,5,6-tetrahydro-6-phenylimidazo[2.1-BETA]thiazole hydrochloride.
Chirigos MA; Fuhrman F; Pryor J
Cancer Res; 1975 Apr; 35(4):927-31. PubMed ID: 1116150
[TBL] [Abstract][Full Text] [Related]
14. Altered host-allograft relationships for mouse tumors modified by prior passage in vitro and in vivo. II. Reactivity of lymphoid cells.
Jacobs BB
J Natl Cancer Inst; 1972 Oct; 49(4):1085-91. PubMed ID: 4404346
[No Abstract] [Full Text] [Related]
15. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
Henderson LA; Ciavarra R; Riblet R; Forman J
J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
[TBL] [Abstract][Full Text] [Related]
16. Effects of in vivo Friend leukemia virus infection on levels of serum thymic factors and on selected T-cell functions in mice.
Tonietti G; Rossi GB; Del Gobbo V; Accinni L; Ranucci A; Titti F; Premrov MG; Garaci E
Cancer Res; 1983 Sep; 43(9):4355-63. PubMed ID: 6347370
[TBL] [Abstract][Full Text] [Related]
17. A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
Cai Y; Tang XD; Zhou PJ
Scand J Immunol; 2005 Mar; 61(3):266-73. PubMed ID: 15787744
[TBL] [Abstract][Full Text] [Related]
18. Histopathology of the host response to Lewis lung carcinoma: modulation by pyran.
Snodgrass MJ; Morahan PS; Kaplan AM
J Natl Cancer Inst; 1975 Aug; 55(2):455-62. PubMed ID: 1159827
[TBL] [Abstract][Full Text] [Related]
19. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
[TBL] [Abstract][Full Text] [Related]
20. Pyran copolymer as an effective adjuvant to chemotherapy against a murine leukemia and solid tumor.
Mohr SJ; Chirigos MA; Fuhrman FS; Pryor JW
Cancer Res; 1975 Dec; 35(12):3750-4. PubMed ID: 1192431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
